Mouse Model for Drug Screening & Evaluation

Mouse models remain an important preclinical tool for studying pharmacology, toxicology, disease mechanisms, and treatment response before human trials. Their value comes from controllable genetics, relatively short reproductive cycles, established husbandry practices, and the availability of immunodeficient, humanized, transgenic, and patient-derived models. However, findings require careful interpretation because differences in metabolism, immune biology, disease progression, and exposure can limit translation to people. Strong programs therefore combine mouse evidence with in vitro systems, computational analysis, and other relevant animal or human-derived models.

The field is shifting from routine use of standardized strains toward better-matched models that reflect disease heterogeneity, clinically relevant endpoints, and intended mechanisms of action. Patient-derived xenografts, humanized immune systems, genetically engineered strains, and precision phenotyping are being used where conventional models do not adequately represent human biology. Reproducibility is also receiving greater attention through preregistration, randomization, blinding, protocol standardization, transparent reporting, and independent replication. At the same time, the principles of replacement, reduction, and refinement are encouraging lower animal use, improved welfare monitoring, and greater adoption of organoids, cell-based assays, and computational methods.

Artificial intelligence can support mouse-based drug evaluation by linking molecular, imaging, behavioral, laboratory, and histopathology data. Machine-learning methods can help identify phenotypic patterns, prioritize compounds, detect subtle treatment effects, and improve dose or study-arm selection when supported by suitable validation data. Computer vision can reduce observer variation in behavior and pathology assessment, while natural-language and knowledge-graph tools can organize evidence across publications and protocols. These applications do not remove the need for biological judgment: biased training data, non-representative cohorts, weak external validation, and opaque algorithms can produce misleading conclusions. Governance should therefore include predefined endpoints, auditable workflows, data-quality controls, and independent confirmation.

North America combines extensive biomedical infrastructure with mature regulatory expectations for preclinical evidence, while Latin America is expanding research capacity unevenly and often relies on partnerships, shared facilities, and imported specialized resources. Europe places strong emphasis on harmonized standards, animal-welfare regulation, alternatives, and reproducibility, with the Middle East developing biomedical capabilities through institutional investment and international collaboration. Africa has important opportunities in infectious disease, neglected disease, and locally relevant health research but faces constraints in funding, facilities, and specialist capacity. Asia-Pacific includes highly developed pharmaceutical and academic ecosystems alongside rapidly growing research programs, creating demand for standardized models, interoperable data, and regionally relevant disease biology.

ASEAN research programs benefit from regional collaboration, shared infrastructure, and capacity development, while BRICS members span diverse regulatory systems and scientific strengths that can support broader disease-model coverage when data and standards are aligned. The European Union emphasizes coordinated research, animal-welfare requirements, and cross-border data practices. G7 members generally contribute advanced biomedical platforms, strong regulatory science, and established translational networks. GCC countries are investing in biomedical research and precision-health capabilities, with opportunities to build specialized preclinical centers and training pipelines. NATO countries may benefit from collaboration on preparedness, toxicology, infectious disease, and resilience-related research, although scientific exchange remains subject to national security and regulatory considerations.

Australia supports rigorous biomedical research and has particular relevance for infectious disease, immunology, and translational science. Brazil and Mexico provide important settings for disease models relevant to large and diverse populations, while Canada combines strong academic research with expertise in imaging, immunology, and animal care. China and India have broad pharmaceutical and research ecosystems, with continued needs for harmonized reporting and cross-site reproducibility. Japan and South Korea offer advanced biomedical engineering, phenotyping, and drug-development capabilities. France, Germany, Italy, Spain, and the United Kingdom contribute established academic, clinical, and regulatory research networks, alongside strong interest in alternatives and welfare refinement. Russia retains scientific capability in selected biomedical areas, although collaboration, access, and regulatory conditions can affect project execution. In the United States, extensive research infrastructure and regulatory experience support complex model development, while oversight and translation remain central priorities.

Organizations should define the clinical question and target product profile before selecting a strain, disease induction method, endpoint, or exposure schedule. They should use model panels when heterogeneity is material, match pharmacokinetics and pharmacodynamics to human-relevant exposure, and include both biological and technical replication. Study plans should predefine inclusion criteria, randomization, blinding, statistical analysis, stopping rules, and welfare safeguards. Investment in standardized metadata, interoperable imaging and pathology data, and validated analytical pipelines can improve cross-study learning. Finally, decision gates should integrate mouse findings with human-derived assays, translational biomarkers, computational evidence, and early clinical observations rather than treating any single model as definitive.

This executive summary uses a qualitative synthesis of established principles in pharmacology, toxicology, laboratory-animal science, translational medicine, artificial intelligence, and research governance. The assessment compares model types, experimental practices, data workflows, and infrastructure considerations across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific, while incorporating the specified country and international-group contexts. Insights are framed around validated scientific and operational themes rather than numerical market indicators. Because capabilities vary within every geography, regional and country observations should be interpreted as broad research-system characteristics, not uniform statements about every institution.

Mouse models will continue to support drug screening and evaluation where they are biologically appropriate and methodologically well controlled. Their greatest contribution comes from integrating mechanism, exposure, safety, and response data within a broader translational strategy. Progress will depend on selecting models that reflect the intended clinical question, improving reproducibility, adopting humane and efficient study designs, and using artificial intelligence responsibly. Institutions that connect animal evidence with human-relevant systems and transparent decision frameworks will be better positioned to distinguish actionable signals from findings that are unlikely to translate.